Displaying drugs 2751 - 2775 of 2939 in total
Hu-rhEGF-rP64k/Mont
Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).
Investigational
Matched Description: … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically …
NSI-566
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
Matched Description: … NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. …
Eldelumab
MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.
Investigational
Matched Description: … MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association …
Cimlanod
Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers).
Investigational
Matched Description: … Cimlanod is under investigation in clinical trial NCT02819271 (A First-in-Human Study of the Safety of …
Virus Specific T-Cell
Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. Antigens identified as an immune target are presented by antigen-presenting cells (APCs) to T-cells along with other molecules that stimulate their growth and...
Investigational
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
Matched Description: … SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. …
SNX-5422
SNX-5422 is a synthetic, novel, small molecule Hsp90 Inhibitor. As an oral formulation that demonstrates strong efficacy and tolerability, SNX-5422 is positioned as a breakthrough therapy with broad applicability across a wide range of cancers.
Investigational
Rupintrivir
Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
Investigational
Matched Description: … Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV …
SIG-007
SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A. Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.
Investigational
Matched Description: … gene therapy that consists of cells that are genetically modified with a non-viral vector to express human …
HGTV-43
HGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection. HGTV43 is one of a number of so-called 'gene transfer vectors' developed by the biotechnology company Enzo Biochem, Inc.
Investigational
Denibulin
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
CDX-1135
CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed by Avant Immunotherapeutics (now Celldex). It was investigated in clinical trials for post-cardiopulmonary bypass syndrome and kidney damage.
Investigational
Matched Description: … CDX-1135, formerly TP-10, is a soluble, recombinant human Complement Receptor Type 1 (sCR1) developed …
AMG 424
AMG 424 is a novel, humanized, anti-CD3/CD38 bispecific monoclonal antibody being investigated for multiple myeloma.
Investigational
CHF 4227
CHF 4227 is a new selective estrogen receptor modulator (SERM). The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis. Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used...
Investigational
XmAb 2513
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
Investigational
Emricasan
Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
Investigational
Matched Description: … Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA …
Palmidrol
A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).
Experimental
Nutraceutical
Matched Description: … Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes …
XTL-6865
XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
Investigational
Matched Description: … XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis …
RGX-501
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human …
Viralym-C
Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]
Investigational
Matched Description: … It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. …
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
Matched Description: … It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor …
ARGX-119
ARGX-119 is a monoclonal antibody that targets and activates muscle-specific kinase (MuSK).
Investigational
TPX-4589
TPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.
Investigational
16-Bromoepiandrosterone
16-Bromoepiandrosterone is an injectable formulation of a compound called alpha-epi-bromide. It is a chemical relative of DHEA which was selected for development after it showed antiretroviral activity in laboratory tests.
Investigational
Displaying drugs 2751 - 2775 of 2939 in total